Eyenovia (EYEN) has disclosed a new risk, in the Sales & Marketing category.
Eyenovia’s financial future hangs in the balance as its profitability is largely hinged on the success of Mydcombi and clobetasol propionate, the only FDA-approved products in its portfolio. The modest Mydcombi sales of $3,787 in 2023 underscore the company’s ongoing struggle to fully fund operations through product revenue. With a plethora of potential hurdles—ranging from pricing and reimbursement challenges to market acceptance and supply chain stability—Eyenovia’s ability to significantly boost revenue and achieve sustained profitability remains uncertain, casting a shadow over its stock valuation.
The average EYEN stock price target is $11.00, implying 836.17% upside potential.
To learn more about Eyenovia’s risk factors, click here.
